Degarelix is recommended as an option for treating advanced hormone-dependent prostate cancer in patients with spinal metastases in line with NICE TA404. The routine commissioning of degarelix is not accepted in Devon for the management of advanced hormone-dependent prostate cancer in patients without spinal metastases.
| Filename: | Degarelix for advanced hormone dependent prostate cancer in patients without spinal metastases |
| Filetype: | |
| Filesize: | 91.46 KB |
| Date uploaded: | 26th October 2016 |
| Date updated: | 8th December 2022 |
